FR08C0028I2 - - Google Patents

Info

Publication number
FR08C0028I2
FR08C0028I2 FR08C0028C FR08C0028C FR08C0028I2 FR 08C0028 I2 FR08C0028 I2 FR 08C0028I2 FR 08C0028 C FR08C0028 C FR 08C0028C FR 08C0028 C FR08C0028 C FR 08C0028C FR 08C0028 I2 FR08C0028 I2 FR 08C0028I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0028C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR08C0028I1 publication Critical patent/FR08C0028I1/fr
Application granted granted Critical
Publication of FR08C0028I2 publication Critical patent/FR08C0028I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FR08C0028C 1994-10-07 2008-06-27 Active FR08C0028I2 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound
PCT/JP1995/001983 WO1996011210A1 (en) 1994-10-07 1995-09-29 Cyclic hexapeptides having antibiotic activity

Publications (2)

Publication Number Publication Date
FR08C0028I1 FR08C0028I1 (cg-RX-API-DMAC10.html) 2008-08-15
FR08C0028I2 true FR08C0028I2 (cg-RX-API-DMAC10.html) 2009-11-20

Family

ID=26305774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0028C Active FR08C0028I2 (cg-RX-API-DMAC10.html) 1994-10-07 2008-06-27

Country Status (26)

Country Link
US (2) US6107458A (cg-RX-API-DMAC10.html)
EP (1) EP0788511B1 (cg-RX-API-DMAC10.html)
JP (2) JP2897427B2 (cg-RX-API-DMAC10.html)
KR (1) KR100353303B1 (cg-RX-API-DMAC10.html)
CN (1) CN1203089C (cg-RX-API-DMAC10.html)
AR (1) AR041770A1 (cg-RX-API-DMAC10.html)
AT (1) ATE229541T1 (cg-RX-API-DMAC10.html)
AU (1) AU696949B2 (cg-RX-API-DMAC10.html)
BR (2) BRPI9504791B8 (cg-RX-API-DMAC10.html)
CA (1) CA2202058C (cg-RX-API-DMAC10.html)
DE (2) DE69529172T2 (cg-RX-API-DMAC10.html)
DK (1) DK0788511T3 (cg-RX-API-DMAC10.html)
ES (1) ES2187575T3 (cg-RX-API-DMAC10.html)
FI (1) FI119988B (cg-RX-API-DMAC10.html)
FR (1) FR08C0028I2 (cg-RX-API-DMAC10.html)
HU (1) HU228151B1 (cg-RX-API-DMAC10.html)
IL (1) IL115484A (cg-RX-API-DMAC10.html)
LU (1) LU91452I2 (cg-RX-API-DMAC10.html)
MX (1) MX9702531A (cg-RX-API-DMAC10.html)
NL (1) NL300352I2 (cg-RX-API-DMAC10.html)
NO (2) NO328483B1 (cg-RX-API-DMAC10.html)
OA (1) OA10475A (cg-RX-API-DMAC10.html)
PT (1) PT788511E (cg-RX-API-DMAC10.html)
RU (1) RU2165423C2 (cg-RX-API-DMAC10.html)
TR (1) TR199501229A2 (cg-RX-API-DMAC10.html)
WO (1) WO1996011210A1 (cg-RX-API-DMAC10.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
US6291680B1 (en) * 1997-06-18 2001-09-18 Fujisawa Pharmaceutical Co., Ltd. Production process
HUP0102515A3 (en) * 1998-02-09 2001-12-28 Fujisawa Pharmaceutical Co Cyclopeptides, process for their preparation, pharmaceutical compositions comprising thereof and their use
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
AU3492100A (en) * 1999-02-11 2000-08-29 Emisphere Technologies, Inc. Oxadiazole compounds and compositions for delivering active agents
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
AUPP999799A0 (en) 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
WO2001007468A2 (en) * 1999-07-27 2001-02-01 Aventis Pharma Deutschland Gmbh Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
WO2002060446A1 (fr) 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
WO2004014879A1 (en) * 2002-08-08 2004-02-19 Fujisawa Pharmaceutical Co., Ltd. New process
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
EP1654036B1 (en) * 2003-07-22 2007-12-26 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
JP2007504460A (ja) * 2003-09-05 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 固定相及び該固定相を用いた精製プロセス
CN1902177A (zh) * 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
AU2005245470A1 (en) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
CN101083993A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006044502A2 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
PL2786992T3 (pl) 2007-08-13 2018-04-30 Monsanto Technology Llc Kompozycje i sposoby zwalczania nicieni
KR20100075892A (ko) * 2007-10-29 2010-07-05 아스테라스 세이야쿠 가부시키가이샤 폴리펩티드 화합물
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
CN102076670B (zh) * 2008-06-24 2013-05-22 Irm责任有限公司 调节g蛋白偶联受体的化合物和方法
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
US9132163B2 (en) 2011-04-20 2015-09-15 Xellia Pharmaceuticals Aps Method for purification of Micafungin
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
ES2586408T3 (es) * 2011-09-09 2016-10-14 Sandoz Ag Preparación de intermedios de micafungina
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
CN102659930B (zh) 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627689B (zh) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
US20170190742A1 (en) * 2014-05-29 2017-07-06 Shanghai Techwell Biopharmaceutical Co., Ltd. Composition of cyclic peptide compound, preparation method for same, and uses thereof
EP3150623B1 (en) * 2014-05-29 2019-04-03 Shanghai Techwell Biopharmaceutical Co., Ltd Solvate of cyclic peptide compound, preparation method for same, and uses thereof
WO2016056023A2 (en) * 2014-10-07 2016-04-14 Alaparthi Lakshmi Prasad Intermediates and processes to prepare micafungin
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
PL3554474T3 (pl) 2016-12-16 2024-04-15 Baxter International Inc. Kompozycje mykafunginy
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin
CN108752430B (zh) * 2018-05-31 2022-02-18 杭州中美华东制药有限公司 米卡芬净钠新晶型及其制备方法
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ｐｔｐ－１ｂ阻害剤およびその用途
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法
CN115785226A (zh) * 2021-09-09 2023-03-14 上海天伟生物制药有限公司 一种棘白菌素药物杂质及其制备、纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1574603A1 (ru) * 1988-08-11 1990-06-30 Ивановский Химико-Технологический Институт Способ получени мезо-тетраарилоктаметилпорфиринов
IL98506A (en) * 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
IL122315A (en) * 1992-03-19 2002-03-10 Lilly Co Eli Cyclic peptides and antifungal pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ES2187575T3 (es) 2003-06-16
JP3518665B2 (ja) 2004-04-12
JPH10507174A (ja) 1998-07-14
ATE229541T1 (de) 2002-12-15
NO2010016I2 (no) 2011-10-17
NO971544D0 (no) 1997-04-04
KR970707150A (ko) 1997-12-01
HK1004136A1 (en) 1998-11-20
EP0788511A1 (en) 1997-08-13
IL115484A (en) 2000-07-16
FR08C0028I1 (cg-RX-API-DMAC10.html) 2008-08-15
BRPI9504791B8 (pt) 2019-12-31
CA2202058C (en) 2007-11-06
NO2010016I1 (no) 2010-08-16
DE122008000025I1 (de) 2008-08-21
CA2202058A1 (en) 1996-04-18
DK0788511T3 (da) 2003-03-31
AU3578095A (en) 1996-05-02
RU2165423C2 (ru) 2001-04-20
US6265536B1 (en) 2001-07-24
FI971397L (fi) 1997-05-27
MX9702531A (es) 1997-06-28
NO328483B1 (no) 2010-03-01
FI119988B (fi) 2009-05-29
DE69529172T2 (de) 2003-04-17
AU696949B2 (en) 1998-09-24
LU91452I2 (fr) 2008-08-04
PT788511E (pt) 2003-04-30
JPH10324695A (ja) 1998-12-08
AR041770A1 (es) 2005-06-01
TR199501229A2 (tr) 1996-07-21
DE69529172D1 (de) 2003-01-23
BR9504791A (pt) 1996-10-22
CN1203089C (zh) 2005-05-25
DE122008000025I2 (de) 2011-02-17
EP0788511B1 (en) 2002-12-11
OA10475A (en) 2002-04-08
IL115484A0 (en) 1996-01-19
NL300352I2 (nl) 2008-11-03
FI971397A0 (fi) 1997-04-04
WO1996011210A1 (en) 1996-04-18
HUT77736A (hu) 1998-07-28
NL300352I1 (nl) 2008-08-01
CN1168675A (zh) 1997-12-24
NO971544L (no) 1997-06-04
JP2897427B2 (ja) 1999-05-31
US6107458A (en) 2000-08-22
HU228151B1 (en) 2012-12-28
BR9504791B1 (pt) 2010-10-05
KR100353303B1 (ko) 2003-01-15

Similar Documents

Publication Publication Date Title
TW281822B (cg-RX-API-DMAC10.html)
TW285654B (cg-RX-API-DMAC10.html)
DK105996A (cg-RX-API-DMAC10.html)
BRPI9507160A (cg-RX-API-DMAC10.html)
EP0669187A3 (cg-RX-API-DMAC10.html)
EP0667387A3 (cg-RX-API-DMAC10.html)
BR9509661A (cg-RX-API-DMAC10.html)
TW279989B (cg-RX-API-DMAC10.html)
BY1704C1 (cg-RX-API-DMAC10.html)
ECSDI940213S (cg-RX-API-DMAC10.html)
ECSDI940180S (cg-RX-API-DMAC10.html)
ECSDI940203S (cg-RX-API-DMAC10.html)
ECSMU940030U (cg-RX-API-DMAC10.html)
ECSDI940194S (cg-RX-API-DMAC10.html)
ECSMU940033U (cg-RX-API-DMAC10.html)
ECSDI940190S (cg-RX-API-DMAC10.html)
ECSDI940185S (cg-RX-API-DMAC10.html)
ECSDI940183S (cg-RX-API-DMAC10.html)
ECSDI940182S (cg-RX-API-DMAC10.html)
ECSMU940034U (cg-RX-API-DMAC10.html)
DK40195A (cg-RX-API-DMAC10.html)
CN3026925S (cg-RX-API-DMAC10.html)
EP0664105A3 (cg-RX-API-DMAC10.html)
CN3029140S (cg-RX-API-DMAC10.html)
CN3028520S (cg-RX-API-DMAC10.html)